Larimar Therapeutics Inc (LRMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -62,395 | -29,613 | -165,673 | -103,175 | -55,463 |
| Depreciation Amortization | -299 | -16 | -1,348 | -1,278 | -1,041 |
| Accounts payable and accrued liabilities | 2,368 | 2,925 | 2,792 | 8,625 | 1,722 |
| Other Working Capital | -29,981 | -16,879 | 47,097 | 24,534 | 7,054 |
| Other Operating Activity | 1,663 | -1,031 | 3,931 | -3,380 | 1,807 |
| Operating Cash Flow | $-88,644 | $-44,614 | $-113,201 | $-74,674 | $-45,921 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -11,781 | 29,000 | 100,400 | 66,400 | 33,358 |
| PPE Investments | -130 | N/A | -91 | -91 | -68 |
| Investing Cash Flow | $-11,911 | $29,000 | $100,309 | $66,309 | $33,290 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 107,680 | 108,115 | 65,086 | 65,287 | N/A |
| Financing Cash Flow | $107,680 | $108,115 | $65,086 | $65,287 | $N/A |
| Beginning Cash Position | 86,018 | 86,018 | 33,824 | 33,824 | 33,824 |
| End Cash Position | 93,143 | 178,519 | 86,018 | 90,746 | 21,193 |
| Net Cash Flow | $7,125 | $92,501 | $52,194 | $56,922 | $-12,631 |
| Free Cash Flow | |||||
| Operating Cash Flow | -88,644 | -44,614 | -113,201 | -74,674 | -45,921 |
| Capital Expenditure | -130 | N/A | -91 | -91 | -68 |
| Free Cash Flow | -88,774 | -44,614 | -113,292 | -74,765 | -45,989 |